Undisclosed intracellular RNA

Undisclosed intracellular RNA is a placeholder designation used in pharmaceutical pipelines to describe a proprietary ribonucleic acid sequence or structure targeted for therapeutic purposes (Nature Reviews Drug Discovery, 2017). These targets are typically located within the cytoplasm or nucleus and are often pursued using small molecule drugs designed to bind to specific RNA secondary or tertiary motifs, such as hairpins, bulges, or G-quadruplexes (Journal of Medicinal Chemistry, 2021). By interacting with these structures, drugs can modulate essential biological processes such as alternative splicing, mRNA stability, or protein translation (Nucleic Acids Research, 2020). This approach is particularly relevant for addressing 'undruggable' proteins by intervening at the transcript level rather than the protein level (Trends in Pharmacological Sciences, 2018). Because the specific identity of the RNA (e.g., a specific mRNA, lncRNA, or pre-mRNA) is withheld for intellectual property reasons, it represents a broad class of emerging targets in oncology, neurology, and rare genetic diseases (Biochemistry, 2019).

Other names

Undisclosed RNA targetProprietary RNA targetIntracellular RNA

Modulation of RNA function through small molecule binding to specific structural motifs, leading to altered splicing, inhibition of translation, or induced degradation.